Current Report Filing (8-k)
April 08 2022 - 4:31PM
Edgar (US Regulatory)
0001314052
false
0001314052
2022-04-07
2022-04-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 7, 2022
ANAVEX
LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
Nevada |
001-37606
|
98-0608404
|
(State or other jurisdiction
|
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
630
5th Avenue
20th
Floor
New
York, NY 10111
(Address
of principal executive offices) (Zip Code)
1-844-689-3939
(Registrant’s
telephone number, including area code)
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered
pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol |
|
Name
of Each Exchange on Which Registered |
Common
Stock, par value $0.001 per share |
|
AVXL |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective April 7, 2022, Anavex
Life Sciences Corp., a Nevada corporation (the “Company”), entered into the Third Amendment to Employment Agreement
(the “Amendment”) with Christopher Missling, PhD (“Dr. Missling”), in his continuing capacity as
Chief Executive Officer of the Company. The Amendment amends the Second Amendment to Employment Agreement dated May 3, 2019, the First
Amendment to Employment Agreement dated July 5, 2016, and the Employment Agreement by and between the Company and Dr. Missling, dated
June 27, 2013 (as amended, the “Employment Agreement”).
The Amendment is made to extend
the term of the Employment Agreement through July 5, 2025, unless earlier terminated as provided in the Amendment. Pursuant to the terms
of the Amendment, beginning July 5, 2022, the CEO shall receive an annual base salary of $700,000 and is eligible to earn an annual cash
target bonus for each whole or partial calendar year of twenty percent of his base salary. Subject to the terms of the Amendment, the
CEO will also receive 500,000 options for shares of the Company’s common stock, which will vest upon the achievement of three pre-defined
performance objectives. The options shall have an exercise price equal to the closing price of the Company’s common stock on the
date of grant.
The summary of the Amendment provided
herein is qualified in its entirety by the terms of such agreement, which are fully set forth and attached hereto as Exhibit 10.1 and
which are incorporated by reference herein.
Item 9.01 |
Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ANAVEX LIFE SCIENCES CORP. |
|
|
|
By: |
/s/Christopher Missling |
|
|
Name: Christopher Missling, PhD
Title: Chief Executive Officer |
Date: April 8, 2022
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2023 to Apr 2024